P53 and Cyclooxygenase-2 Expression Are Directly Associated with Cyclin D1 Expression in Radical Prostatectomy Specimens of Patients with Hormone-naïve Prostate Cancer

Overview

Journal Pathol Oncol Res

Specialty Oncology

Date 2011 Jul 26

PMID 21786090

Citations 1

Authors

Panagiotis J Vlachostergios

Foteini Karasavvidou

Anna Patrikidou

Ioannis A Voutsadakis

Grigorios Kakkas

George Moutzouris

Elias Zintzaras

Danai D Daliani

Michael D Melekos

Christos N Papandreou

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PCa) is a potentially curable disease when diagnosed in early stages and subsequently treated with radical prostatectomy (RP). However, a significant proportion of patients tend to relapse early, with the emergence of biochemical failure (BF) as an established precursor of progression to metastatic disease. Several candidate molecular markers have been studied in an effort to enhance the accuracy of existing predictive tools regarding the risk of BF after RP. We studied the immunohistochemical expression of p53, cyclooxygenase-2 (COX-2) and cyclin D1 in a cohort of 70 patients that underwent RP for early stage, hormone naïve PCa, with the aim of prospectively identifying any possible interrelations as well as correlations with known prognostic parameters such as Gleason score, pathological stage and time to prostate-specific antigen (PSA) relapse. We observed a significant (p = 0.003) prognostic role of p53, with high protein expression correlating with shorter time to BF (TTBF) in univariate analysis. Both p53 and COX-2 expression were directly associated with cyclin D1 expression (p = 0.055 and p = 0.050 respectively). High p53 expression was also found to be an independent prognostic factor (p = 0.023). Based on previous data and results provided by this study, p53 expression exerts an independent negative prognostic role in localized prostate cancer and could therefore be evaluated as a useful new molecular marker to be added in the set of known prognostic indicators of the disease. With respect to COX-2 and cyclin D1, further studies are required to elucidate their role in early prediction of PCa relapse after RP.

Citing Articles

Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.

Sequeiros T, Garcia M, Montes M, Olivan M, Rigau M, Colas E Biomed Res Int. 2013; 2013:283635.

PMID: 24371818 PMC: 3859157. DOI: 10.1155/2013/283635.

References

Brooks J, Bova G, Ewing C, Piantadosi S, Carter B, Robinson J . An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res. 1996; 56(16):3814-22. View

Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P . Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res. 2001; 29(1):23-8. DOI: 10.1007/s002400000148. View

Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J . Expression of cyclooxygenase-2 in prostate carcinoma. Cancer. 2000; 89(3):589-96. View

Osman I, Yee H, Taneja S, Levinson B, Zeleniuch-Jacquotte A, Chang C . Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res. 2004; 10(12 Pt 1):4096-100. DOI: 10.1158/1078-0432.CCR-04-0120. View

Moul J, Bettencourt M, Sesterhenn I, Mostofi F, McLeod D, Srivastava S . Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery. 1996; 120(2):159-66; discussion 166-7. DOI: 10.1016/s0039-6060(96)80283-2. View

Brewster S, Oxley J, Trivella M, Abbott C, Gillatt D . Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol. 1999; 161(4):1238-43. View

Shappell S, Manning S, Boeglin W, Guan Y, Roberts R, Davis L . Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia. 2001; 3(4):287-303. PMC: 1505867. DOI: 10.1038/sj.neo.7900166. View

Oxley J, Winkler M, Parry K, Brewster S, Abbott C, Gillatt D . p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy. BJU Int. 2002; 89(1):27-32. View

Goto T, Nguyen B, Nakano M, Ehara H, Yamamoto N, Deguchi T . Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population. Urology. 2008; 72(1):167-71. DOI: 10.1016/j.urology.2007.11.003. View

10.

Rubio J, Ramos D, Lopez-Guerrero J, Iborra I, Collado A, Solsona E . Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol. 2005; 48(5):745-51. DOI: 10.1016/j.eururo.2005.06.014. View

11.

Denkert C, Thoma A, Niesporek S, Weichert W, Koch I, Noske A . Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1. Prostate. 2007; 67(4):361-9. DOI: 10.1002/pros.20467. View

12.

Edwards J, Mukherjee R, Munro A, Wells A, Almushatat A, Bartlett J . HER2 and COX2 expression in human prostate cancer. Eur J Cancer. 2003; 40(1):50-5. DOI: 10.1016/j.ejca.2003.08.010. View

13.

Bauer J, Sesterhenn I, Mostofi F, McLeod D, Srivastava S, Moul J . Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol. 1996; 156(4):1511-6. View

14.

Lee L, Pan C, Cheng C, Chi C, Liu T . Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res. 2001; 21(2B):1291-4. View

15.

Stapleton A, Zbell P, Kattan M, Yang G, Wheeler T, Scardino P . Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer. 1998; 82(1):168-75. DOI: 10.1002/(sici)1097-0142(19980101)82:1<168::aid-cncr21>3.0.co;2-#. View

16.

Bartkova J, Lukas J, Strauss M, Bartek J . Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene. 1995; 10(4):775-8. View

17.

Leibovich B, Cheng L, Weaver A, Myers R, Bostwick D . Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer. J Urol. 2000; 163(6):1756-60. View

18.

Revelos K, Petraki C, Gregorakis A, Scorilas A, Papanastasiou P, Koutsilieris M . Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res. 2005; 25(4):3123-33. View

19.

Pruthi R, Derksen E, Gaston K . Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol. 2003; 169(6):2352-9. DOI: 10.1097/01.ju.0000047364.56051.74. View

20.

Shurbaji M, Kalbfleisch J, Thurmond T . Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol. 1995; 26(1):106-9. DOI: 10.1016/0046-8177(95)90122-1. View